Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 31, 2008

SAFC Initiates Second Phase of a $600K Research Facility Expansion

  • SAFC has begun the second-phase of a $600,000 expansion of its solid-state services Pharmorphix research facility in Cambridge, U.K. The building will include 7,500 sq. ft. of laboratory capacity.

    The fully refitted space is scheduled for completion in the first quarter and will augment the existing 12,500 sq. ft. site. The development includes office reorganization and will facilitate installation later this year of additional spectroscopic and diffraction equipment.

    Recently, SAFC announced the $12 million expansion of SAFC Pharma's viral product manufacturing facility in Carlsbad, CA. Additionall, the company reported the launch of Pharmorphix services in the U.S. at its flagship manufacturing facility in Madison, WI. This facility will be equipped with new XRPD (X-ray powder diffraction) analytical equipment.

    Other recently announced investments include a $10 million expansion of commercial-scale APIs manufacturing and storage capacity, respectively, at Arklow, Ireland and Buchs, Switzerland, a $29 million potent-fermentation expansion in Jerusalem, Israel, and a high-potent API conjugation suite at its St Louis, MO, manufacturing campus.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »